Overview

T-Cell Depletion and Stem Cell Transplant for Immune Deficiencies and Histiocytic Disorders

Status:
Terminated
Trial end date:
2015-08-01
Target enrollment:
Participant gender:
Summary
The hypothesis is to determine if a preparative regimen of busulfan, cyclophosphamide, and antithymocyte globulin (ATG) plus allogeneic stem cell transplantation will be effective in the treatment of immune deficiencies and histiocytic disorders.
Phase:
Phase 2/Phase 3
Details
Lead Sponsor:
Masonic Cancer Center, University of Minnesota
Treatments:
Busulfan